Insider buying last 90 days
No open-market insider purchases were filed for AKTS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AKTS insider filing, plotted on the chart in Gekko.Open AKTS in Gekko
NASDAQ: AKTS
Aktis Oncology (AKTS) Stock Analysis & Forecast
Oct 12 close
$17.34−0.81 (−4.5%)
Gekko Brief
AI summaryOct 12 closeThe only headline on Aktis Oncology this week concerns a filing from Mirador Capital Partners LP, which raised its stake by 232.9%, adding 93,434 shares to bring its total to 133,558 shares, with institutional investors now holding 28.84% of the company collectively.
AKTS closed at $17.34, down 4.5% on the day, and sits well below its 50-day moving average of $22.76, with a 52-week range spanning $14.72 to $34.19. The shares have fallen 25.6% over the past month and 31.1% over the past three months. The GekkoIndex reads 70.2, placing the stock in the Buying zone, while the price remains 29.3% below the Gekko Fair Value of $24.54.
Over the next 20 trading days, the next earnings report is due 12 November 2026, 31 days away and outside a typical 20-trading-day hold; the prior report on 10 August 2026 showed an EPS of -0.44 against an estimate of -0.44, with a 2.7% reaction, against an average absolute reaction of 10.3% across recent quarters. One trailblazer holder is noted in current positioning. Six covering firms carry a buy rating with no holds or sells, and a consensus target of $35.39, implying 104.1% consensus upside. The gap to Gekko Fair Value bears watching given the scale of the recent decline.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Aktis Oncology price vs fair value
Close $17.34Gekko Fair Value $24.54
Aktis Oncology quick facts
- Market cap
- $926.0M
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$1.70
- Revenue, TTM
- $10.06M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- —
- Volume
- 274,045 avg 506,397
- 1-year return
- —
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±11.1%
- 50-day average
- $22.76
- 200-day average
- —
- Next earnings
- Nov 12
- Shares outstanding
- 53.75M
Aktis Oncology swing-trade checklist
Aktis Oncology scores 3 supportive, 0 mixed and 0 headwinds across the 3 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed0 headwinds
- Trendno data
No data
Not enough price history for both moving averages.
See the chart - GekkoIndexsupportive
70.2, Buying
Reading 70.2 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
29.3% below
Price is 29.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Nov 12, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Aktis Oncology stock chart and price history
Aktis Oncology closed at $17.34 on Oct 12, 2026, inside a 52-week range of $14.72 to $34.19.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −25.6%
- 3 months
- −31.1%
- 6 months
- 0.0%
The full AKTS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AKTS in Gekko
Follow Aktis Oncology through every session
Put AKTS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AKTS in GekkoFree for 7 days. No credit card required.
About Aktis Oncology
Aktis Oncology works on radiopharmaceutical treatments for cancer, built around a miniprotein radioconjugate platform designed to carry tumor-killing radioisotopes directly to diseased cells. The company remains in the clinical stage of development, with its research centered on finding ways to target tumors precisely rather than treating the body broadly.
Its pipeline includes several named programs. One candidate targets Nectin-4 for locally advanced or metastatic urothelial cancer, while AKY-1189 is aimed at Nectin-4 expressing tumors across a broader set of cancers, including breast, non-small cell lung, colorectal, and cervical cancer. A separate program, AKY-2519, is being developed to reach tumors expressing B7-H3 (CD276), with potential application in prostate cancer, lung cancer, and other solid tumors.
The company was originally incorporated under the name HotKnot Therapeutics and took on its current name in April 2020, the same year it was founded. Aktis Oncology is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ under the ticker AKTS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- aktisoncology.com
Aktis Oncology GekkoIndex: the smart money zone
Aktis Oncology’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.2, in the Buying zone, down 0.2 points over five sessions.
70.2Buying
Down 0.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 24 | −2.0% | −2.2% | ||
| Accumulation | 65 | −0.4% | +5.8% | ||
| Neutral | 84 | +0.7% | +1.1% | ||
| Distribution | 11 | +1.0% | −17.5% | ||
| Selling | 0 | Not available | |||
Average AKTS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the AKTS price, zone by zone.Track AKTS in Gekko
Is Aktis Oncology stock overvalued? Gekko Fair Value
Aktis Oncology trades 29.3% below Gekko Fair Value of $24.54, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Aktis Oncology shares are worth, recalculated every trading day.
$24.54
Gekko Fair Value, Oct 10, 2026
29.3% Undervalued
At the end of Aug 2026 the price was 18.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open AKTS in Gekko
Aktis Oncology insider and Congress trading
No open-market insider purchases were filed for Aktis Oncology, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AKTS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AKTS, plotted on the chart in Gekko.Open AKTS in Gekko
Hedge funds and billionaires quarter ended Mar 31
1of the funds Gekko tracks holds AKTS.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Aktis Oncology earnings: next date and track record
Aktis Oncology reports on Nov 12, 2026 (31 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 12, 2026
31 days away
- EPS estimate
- −$0.47
- Revenue estimate
- $3.83M
3 of 8reports beat the EPS estimate
±10.3%average move across the report
2 of 2reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.44 est −$0.44 | $3.38M est $2.70M | +2.7% |
| Mar 30, 2026 | −$0.28 est −$1.15 | $1.87M est $3.28M | +17.8% |
| Dec 19, 2025 | −$16.06 est $0.00 | — | — |
| Nov 14, 2024 | −$0.04 est −$0.08 | — | — |
| May 13, 2024 | −$0.14 est −$0.12 | — | — |
| Feb 13, 2024 | −$0.19 est −$0.18 | — | — |
| Nov 13, 2023 | −$0.27 est −$0.18 | — | — |
| May 8, 2023 | −$0.20 est −$0.21 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Aktis Oncology stock forecast and analyst price targets
Analysts’ average 12-month price target for Aktis Oncology is $35.39, +104.1% from the last close, from 6 firms rating the stock in the last 90 days.
$35.39consensus 12-month target, +104.1% from the last close
Now $17.34Avg $35.39
Low $33High $40
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 2 | Wedbush | $35 | +101.8% |
| Sep 9 | Oppenheimer | $40 | +130.7% |
| Aug 19 | Wedbush | $35 | +101.8% |
| Aug 18 | BMO Capital | $37 | +113.4% |
| Aug 14 | Bank of America Securities | $34 | +96.1% |
−2.2%average 20-day move after past Buying readings
±5.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Aktis Oncology market cap and key statistics
Aktis Oncology’s market cap is $926.0M and revenue of $10.06M over the last twelve months.
Valuation
- Market cap
- $926.0M
- EPS, TTM
- −$1.70
- Gekko Fair Value
- $24.54
Trading
- Volume
- 274,045
- Avg volume, 20 days
- 506,397
- 52-week high
- $34.19
- 52-week low
- $14.72
- Shares outstanding
- 53.75M
Financials
- Revenue, TTM
- $10.06M
- Profit margin
- 0%
- Return on equity
- -29.4%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±11.1%
Aktis Oncology stock news this week
1 headline about Aktis Oncology from the past week, newest first, each linking to the publisher.
Aktis Oncology peers
Aktis Oncology’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Aktis Oncology stock FAQ
What is Aktis Oncology’s market cap?
Aktis Oncology’s market cap is $926.0M at the Oct 12, 2026 close of $17.34, with 53.75M shares outstanding.
What is the Aktis Oncology stock forecast?
The consensus analyst 12-month price target for Aktis Oncology is $35.39, +104.1% from the last close. Of the 6 firms that rated the stock in the last 90 days, 6 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Aktis Oncology stock overvalued or undervalued?
On Gekko’s estimate Aktis Oncology is undervalued: the Oct 12, 2026 close of $17.34 is 29.3% below Gekko Fair Value of $24.54. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Aktis Oncology report earnings next?
Aktis Oncology is expected to report on Nov 12, 2026 (31 days away). Analysts expect earnings of −$0.47 per share on revenue of $3.83M. Aktis Oncology beat the earnings estimate in 3 of its last 8 reports, moving 10.3% on average across the report.
What is Aktis Oncology’s 52-week high and low?
Aktis Oncology’s 52-week high is $34.19 and its 52-week low is $14.72; it closed at $17.34 on Oct 12, 2026.
Is Aktis Oncology stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 3 items with data read as supportive (gekkoindex, fair value and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Aktis Oncology the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.